Fox Run Management L.L.C. Sells 2,077 Shares of Axon Enterprise, Inc $AXON

Key Points

• Fox Run Management L.L.C. has decreased its holdings in Axon Enterprise by 73.3%, reducing its position to 758 shares worth approximately $399,000.
• Major brokerages have raised their price targets for Axon Enterprise, with Goldman Sachs increasing its target from $730 to $830, reflecting positive analyst sentiment towards the stock.
• Axon Enterprise reported strong quarterly earnings, with $2.12 earnings per share, significantly exceeding analysts' expectations of $1.54 and showcasing a 32.6% revenue increase year-over-year.

Fox Run Management L.L.C. lowered its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 73.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 758 shares of the biotechnology company's stock after selling 2,077 shares during the quarter. Fox Run Management L.L.C.'s holdings in Axon Enterprise were worth $399,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AXON. LaSalle St. Investment Advisors LLC increased its holdings in shares of Axon Enterprise by 2.1% during the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock worth $408,000 after buying an additional 16 shares during the last quarter. Pinion Investment Advisors LLC increased its holdings in Axon Enterprise by 3.0% in the 1st quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 19 shares in the last quarter. Kentucky Retirement Systems increased its holdings in Axon Enterprise by 0.4% in the 1st quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock valued at $2,605,000 after purchasing an additional 19 shares in the last quarter. WCM Investment Management LLC grew its stake in shares of Axon Enterprise by 0.8% during the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company's stock valued at $1,306,000 after acquiring an additional 19 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC grew its stake in shares of Axon Enterprise by 0.5% during the first quarter. Sheaff Brock Investment Advisors LLC now owns 3,561 shares of the biotechnology company's stock valued at $1,873,000 after acquiring an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Analysts Set New Price Targets

AXON has been the topic of several research analyst reports. Raymond James Financial reaffirmed an "outperform" rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. JMP Securities raised their price objective on shares of Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a research note on Tuesday, July 22nd. Barclays lifted their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Bank of America lifted their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Finally, Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research note on Tuesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus target price of $837.69.

Insider Transactions at Axon Enterprise

In other news, CRO Cameron Brooks sold 3,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the transaction, the executive owned 19,447 shares in the company, valued at approximately $14,405,559.72. The trade was a 13.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 15,919 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,790 shares of company stock worth $33,654,451. Corporate insiders own 4.40% of the company's stock.

Axon Enterprise Stock Up 0.4%

Shares of AXON stock traded up $2.73 on Friday, hitting $766.24. The company's stock had a trading volume of 395,415 shares, compared to its average volume of 739,771. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a fifty-two week low of $346.71 and a fifty-two week high of $885.91. The firm's fifty day moving average price is $773.05 and its 200-day moving average price is $674.05. The stock has a market capitalization of $60.15 billion, a price-to-earnings ratio of 189.20, a P/E/G ratio of 28.02 and a beta of 1.36.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business's quarterly revenue was up 32.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.